Skip to content ↓

Resources

Featured

Sept. 18: SHYFT hosts ISPOR Fall Networking Event

Please join us at the ISPOR Boston Chapter Fall event to network with fellow Boston members representing: academia, manufacturer, payer/HTA/nontraditional, consulting, and non-HEOR or market…

Specialty Pharmacy Summit 2020

May 4 – 7, 2020 | Las Vegas, NV SHYFT is excited to announce our participation in the Specialty Pharmacy Summit’s Annual Meeting.  Stay…

Sept. 18: SHYFT hosts ISPOR Fall Networking Event

Please join us at the ISPOR Boston Chapter Fall event to network with fellow Boston members representing: academia, manufacturer, payer/HTA/nontraditional, consulting, and non-HEOR or market…

ISPOR 2020

May 16-20, 2020 | Orlando, Florida SHYFT will be attending the ISPOR Annual Conference.  Stay tuned for more information and learn more about the conference…

American Society of Hematology Annual Meeting (ASH)

American Society of Hematology Annual Meeting (ASH) December 7-9 | Orlando, FL SHYFT will be attending the 61st ASH (American Society of Hematology) annual meeting…

Categories:
All
Articles
Events
Industry Insights
Webinars
White Papers

Recent Posts

Sept. 18: SHYFT hosts ISPOR Fall Networking Event
Events

Sept. 18: SHYFT hosts ISPOR Fall Networking Event

Please join us at the ISPOR Boston Chapter Fall event to network with fellow Boston members representing: academia, manufacturer, payer/HTA/nontraditional, consulting, and non-HEOR or market access practice setting.  Each practice setting discussion will be led by roundtable leaders, who will share their own career journeys that led them to their…

SHYFT Posters Presented at ISPOR EU
News

SHYFT Posters Presented at ISPOR EU

SHYFT recently presented a number of scientific posters at the ISPOR EU Annual Meeting.  To view all the posters presented, click here.

Infographic: The State of Real World Evidence
Industry Insights

Infographic: The State of Real World Evidence

The Current State of Real-World Evidence: Trends in Approach Across All Biopharmas
Industry Insights

The Current State of Real-World Evidence: Trends in Approach Across All Biopharmas

The value of and need for Real-World Evidence (RWE) is growing in biopharma: one study predicts that the global market will see a 15 percent compound annual growth rate (CAGR) from 2019 to 2024, reaching $1.64 billion1. Across the lifecycle — from research and development (R&D), to pre-launch…

Real-World Evidence Challenges for Today’s Biopharma
Industry Insights

Real-World Evidence Challenges for Today’s Biopharma

The rapid development of technology — and the resulting avalanche of data — are catalysts for significant change in the biopharmaceutical industry. This translates into urgent pressures for today’s biopharma, including a need to quickly and affordably develop products with proven therapeutic efficacy and value. This urgency is…